Early diagnosis and management can help slow progression.
ACP-01 has been used as a therapy to reverse vascular dementia. We are enrolling participants in a Phase I clinical trial to study the safety, efficacy, and clinical relevancy of ACP-01 as a treatment for vascular dementia.
Symptoms
Vascular dementia is caused by reduced blood flow to the brain, often due to other vascular conditions.
Symptoms can vary depending on the affected brain regions but commonly include:
ACP-01 increases brain function by:
1. Releasing high levels of Interleukin 8 (Chemokine CXCL8), which results in increased expression of Nuclear Factor Kappa B (NFKB)
NFKB is essential for the formation of long term memory. NFKB promotes gene expression essential to the formation of neurite outgrowth, neural plasticity and neural cell longevity.
In the nervous system, NFKB exerts an anti-apoptotic effect (anti cell death effect).
2. Improving microcirculation (angiogenesis). This is because ACP-01 :
Is programmed to form blood vessels.
Exert a potent paracrine effect, secreting vascular endothelial growth factor (VEGF) and angiogenin. Note the high levels of VEGF and Angiogenin associated with ACP-01, as compared to controls.
Are enriched with CD34+ cells, which amplify the angiogenic response to improve circulation.
3. Promotion of cell migration to areas of decreased blood flow (ischemia) and injured brain tissue (stroke) results from:
Expression of surface receptors (CXCR4) on the ACP-01, which home toward signalling proteins (chemokine CXCL12) released by injured brain or stroke. These cells embed, and repopulate injured brain, releasing nerve growth factors.
3. Release Interleukin 8 (Chemokine CXCL8) which:
Improve healing and regeneration, and decrease scarring of injured brain tissue, by attracting cells (microglia) that clear cell debris, but minimize inflammation. This results from ACP-01’s promotion of the “M2 anti-inflammatory” healing.
These mechanisms collectively contribute to observed clinical improvements.
Treatment Outcomes
Hemostemix’s ACP-01 therapy has peer reviewed published benefits that improve (decrease) symptoms of chronic stable angina, particularly in reducing chest pain at rest, enhancing exercise capacity and reducing angina severity as measured by the Canadian Cardiovascular Society (CCS) grading system.Scientific Basis for ACP-01’s Efficacy:
